Anzeige
Mehr »
Login
Sonntag, 24.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Microsofts, Googles und Amazons nukleares Wettrennen macht diese Uranaktie zu einem Muss!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A143G8 | ISIN: FR0013018124 | Ticker-Symbol: NXOA
Frankfurt
22.11.24
21:49 Uhr
0,170 Euro
+0,001
+0,36 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
NICOX SA Chart 1 Jahr
5-Tage-Chart
NICOX SA 5-Tage-Chart
RealtimeGeldBriefZeit
0,1880,25123.11.

Aktuelle News zur NICOX Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiNICOX SA: Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial241Press Release Nicox Announces Publication of the Adaptive Design Period of the NCX 470 Mont Blanc Phase 3 Trial An adaptive design is a useful clinical trial design tool which allowed identification...
► Artikel lesen
17.10.Nicox reports 1H results3
NICOX Aktie jetzt für 0€ handeln
17.10.NICOX SA: Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results237Press Release Nicox Provides Third Quarter 2024 update and First Half 2024 Financial Results Topline results from the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial expected in Q3...
► Artikel lesen
14.10.NICOX SA: Nicox and Soleus Sign $16.5 million Royalty and Equity Financing261Press Release Nicox and Soleus Sign $16.5 million Royalty and Equity Financing Gross proceeds of $15 million (€13.7 million) for the sale of Nicox's net share of the VYZULTA royalty to SoleusSoleus...
► Artikel lesen
23.09.NICOX SA: Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement401Press Release Nicox and Glaukos Sign Exclusive NCX 1728 Research and Global Licensing Option Agreement Option entitles Glaukos to exclusive global license agreements on pre-agreed terms including...
► Artikel lesen
18.09.NICOX SA: Nicox Announces Approval of ZERVIATE in China318Press Release Nicox Announces Approval of ZERVIATE in China Nicox's partner, Ocumension Therapeutics, has received approval for ZERVIATE® for ocular itching in China ZERVIATE® launch in China...
► Artikel lesen
04.09.NICOX SA: Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board374Press Release Nicox Appoints Christine Placet to Board of Directors; Michele Garufi steps down from Board Christine Placet is CFO of Theranexus, and was formerly CEO of Horama and TrophosMichele...
► Artikel lesen
25.07.NICOX SA: Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470254Press Release Nicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470 Recruitment continues in China, on track for topline results in H2 2025 NCX 470 demonstrated...
► Artikel lesen
19.07.NICOX SA: Nicox announces attendance at upcoming conferences272Press Release Nicox announces attendance at upcoming conferencesJuly 19th, 2024 - release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international...
► Artikel lesen
18.07.NICOX SA: Nicox Provides Second Quarter 2024 Update371Press Release Nicox Provides Second Quarter 2024 Update Nicox Group revenue of €1.6 million (net revenue1 €1.0 million) for second quarter 2024Nicox Group cash of €7.8 million on 30 June 2024...
► Artikel lesen
16.07.NICOX SA: Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director279Press Release Nicox appoints experienced biotech leader Damian Marron as Chair of the Board and Marc Le Bozec as Director Damian Marron is an experienced healthcare executive, non-executive Director/Chair...
► Artikel lesen
27.06.NICOX SA: Nicox: 2024 Ordinary Shareholder Meeting259Press Release Nicox: 2024 Ordinary Shareholder MeetingJune 27, 2024 - release at 17:30 CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, ALCOX), an international ophthalmology company...
► Artikel lesen
03.06.NICOX SA: Number of voting rights as of May 31, 20245
03.06.XFRA CAPITAL ADJUSTMENT INFORMATION - 03.06.2024545Das Instrument 6AH KYG063181021 AUSNUTRIA DAIRY HD-,10 EQUITY wird cum Kapitalmassnahme gehandelt am 03.06.2024 und ex Kapitalmassnahme am 04.06.2024 The instrument 6AH KYG063181021 AUSNUTRIA DAIRY...
► Artikel lesen
24.05.NICOX SA: Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024286Press Release Nicox: 2024 Ordinary Shareholder Meeting to be held on June 28th, 2024May 24, 2024 - release at 7:30 am CET Sophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX)...
► Artikel lesen
10.05.XFRA CAPITAL ADJUSTMENT INFORMATION - 10.05.2024324Das Instrument O06 SE0002158568 EASTNINE AB EQUITY wird cum Kapitalmassnahme gehandelt am 10.05.2024 und ex Kapitalmassnahme am 13.05.2024 The instrument O06 SE0002158568 EASTNINE AB EQUITY is traded...
► Artikel lesen
06.05.NICOX SA: Nicox's Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024312Press Release Nicox's Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 Shareholders adopted all resolutions proposed by the Board of Directors at the Ordinary and Extraordinary...
► Artikel lesen
24.04.NICOX SA: Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agent390Press Release Nicox: Second notice of the Ordinary and Extraordinary Shareholders' Meeting on May 6, 2024 and appointment of an ad hoc agentApril 24, 2024 - release at 07:30 CET Sophia Antipolis, FranceNicox...
► Artikel lesen
22.04.NICOX SA: Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results326Press Release Nicox Provides First Quarter 2024 Update and Full Year 2023 Financial Results Nicox Group revenue of €4.4 million (net revenue1 €3.9 million) for first quarter 2024Nicox...
► Artikel lesen
09.04.Nicox: 2024 Ordinary and Extraordinary Shareholder Meeting301Press Release Nicox: 2024 Ordinary and Extraordinary Shareholder MeetingApril 9, 2024 - release at 17:30 CET Sophia Antipolis, FranceNicox SA (Euronext Paris: FR0013018124, ALCOX), an international...
► Artikel lesen
Seite:  Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1